Liang Zheng

Dr. Liang Zheng

Department of Clinical Pharmacology, The Second Hospital of Anhui Medical University, Hefei, China
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YTYunli Tong
Yunli Tong
YLYuting Liu
Yuting Liu
HZHongming Zheng
Hongming Zheng
LZLiang Zheng
Liang Zheng
WLWenqin Liu
Wenqin Liu
LLLinlin Lu
Linlin Lu
Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/-catenin signaling Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling

1 July 2015 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
JSJian Shi
Jian Shi
LZLiang Zheng
Liang Zheng
ZLZhufen Lin
Zhufen Lin
CHChuqi Hou
Chuqi Hou
WLWenqin Liu
Wenqin Liu
ZLZhongqiu Liu
Zhongqiu Liu

8 July 2016 in The AAPS Journal
Verified
Journal Article
Closed access
PDF file
LZLiang Zheng
Liang Zheng
LZLijun Zhu
Lijun Zhu
MZMin Zhao
Min Zhao
JSJian Shi
Jian Shi
YLYuhuan Li
Yuhuan Li
ZLZhongqiu Liu
Zhongqiu Liu

30 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WXWenwen Xu
Wenwen Xu
YXYumeng Xiao
Yumeng Xiao
LZLiang Zheng
Liang Zheng
MXMingyu Xu
Mingyu Xu
XJXuehua Jiang
Xuehua Jiang
LWLing Wang
Ling Wang
Triple-negative breast cancer (TNBC) is a highly aggressive disease with rapid progression and poor prognosis due to multidrug resistance (MDR). Piperine (PIP) shows promise as a P-gp inhibitor, capable of sensitizing chemotherapeutic drugs and exhibiting antitumor properties. This study explores the inhibitory mechanism of PIP on P-glycoprotein (P-gp) and its capacity to enhance the sensitivity of paclitaxel (PTX). We subsequently evaluated the efficacy and safety of albumin nanoparticles that co-encapsulate PTX and PIP (PP@AN). The results demonstrated that PIP enhanced the accumulation of PTX intracellularly, as determined with HPLC/MS/MS analysis. PIP was also found to increase cell sensitivity to PTX. Furthermore, we explored the inhibitory mechanism of PIP on P-gp, utilizing molecular docking simulations, RT-qPCR, and Western blot analysis. PIP appears to compete with the active paclitaxel binding site on P-gp, affecting ATPase activity and downregulating the MDR1 gene and P-gp expression. In summary, PIP could inhibit P-gp and act as a sensitizer in the treatment of TNBC with PTX. Moreover, stable and uniform PP@AN was successfully formulated, resulting in a significant increase in drug accumulation within cells as well as the downregulation of P-gp in tumors at the optimal ratio (PTX:PIP = 1:2). This led to an improvement in the antitumor effect in vivo while also reducing hepatotoxicity and hemototoxicity following chemotherapy. This study comprehensively investigated PIP’s inhibitory effect and mechanism on P-gp. We present a new approach for co-delivering PIP and PTX using albumin nanoparticles, which reduced toxicity and improved therapeutic efficacy both in vivo and in vitro.

12 December 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
WZWei Zhang
Wei Zhang
QZQian Zhang
Qian Zhang
ZCZhihai Cao
Zhihai Cao
LZLiang Zheng
Liang Zheng
HWHU Wei
HU Wei
Rational drug use in special populations is a clinical problem that doctors and pharma-cists must consider seriously. Neonates are the most physiologically immature and vulnerable to drug dosing. There is a pronounced difference in the anatomical and physiological profiles be-tween neonates and older people, affecting the absorption, distribution, metabolism, and excretion of drugs in vivo, ultimately leading to changes in drug concentration. Thus, dose adjustments in neonates are necessary to achieve adequate therapeutic concentrations and avoid drug toxicity. Over the past few decades, modeling and simulation techniques, especially physiologically based pharmacokinetic (PBPK) modeling, have been increasingly used in pediatric drug development and clinical therapy. This rigorously designed and verified model can effectively compensate for the deficiencies of clinical trials in neonates, provide a valuable reference for clinical research design, and even replace some clinical trials to predict drug plasma concentrations in newborns. This review introduces previous findings regarding age-dependent physiological changes and pathological factors affecting neonatal pharmacokinetics, along with their research means. The application of PBPK modeling in neonatal pharmacokinetic studies of various medications is also reviewed. Based on this, we propose future perspectives on neonatal PBPK modeling and hope for its broader application.

1 January 2015 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
ZLZhonghuang Li
Zhonghuang Li
LZLiang Zheng
Liang Zheng
JSJian Shi
Jian Shi
GZGuiyu Zhang
Guiyu Zhang
LLLinlin Lu
Linlin Lu
ZLZhongqiu Liu
Zhongqiu Liu
Matrine is one of the main bioactive alkaloids ofSophora flavescensAiton, which has been widely used to treat various diseases in China. These diseases include viral hepatitis, liver fibrosis, cardiac arrhythmia, skin diseases, and tumors. However, matrine is also the main toxic compound of this herb, and the available biomarkers are not reliable in detecting or quantifying matrine risk. Metabolomics is a powerful tool used to identify early toxicity biomarkers that are specific indicators of damage to biosystems. This study aimed to find the potential biomarkers of the matrine-induced toxic effects in rats and HepG2 cells. The toxicological effects of rats induced by matrine could be derived from the elevated taurine and trimethylamine N-oxide levels and the depletion in hippurate and tricarboxylic acid cycle intermediates, such as 2-oxoglutarate, citrate, and succinate in the urine. Cell metabolomics revealed that the levels of alanine, choline, glutathione, lactate, phosphocholine, and cholesterol showed dose-dependent decreases, whereas the levels of taurine, fatty acid, and unsaturated fatty acid showed dose-dependent increases. Overall, a significant perturbation of metabolites in response to high dose of matrine was observed bothin vivoandin vitro, and the selected metabolites particularly represent an attractive marker for matrine-induced toxicity.